In vitro antiglycation activity of isorhamnetin on bovine serum albumin with different sugars using sodium dodecyl sulphate polyacrylamide gel electrophoresis

Advanced glycation end products (AGEs) resulting from glycation of proteins, lipids and nucleic acids has several pathophysiological manifestations by altering the structure and functions of molecular proteins. Isorhamnetin is a flavonoid with anti-inflammatory, anti-oxidant, anti-obesity, anticancer, antidiabetic and anti-atherosclerosis activity. Based on the structure activity relationship and our insilico antiglycation study of isorhamnetin, we hypothised that isorhamnetin may have antiglycation activity by inhibiting protein glycation on sugar molecules due to its antioxidant and free radical scavenging activity. Hence our aim of the study was to determine the glycation level of bovine serum albumin (BSA) with varying sugar concentration of glucose, fructose and ribose on 14^th and 21^st day of incubation. Our second objective of the study was to determine the antiglycation activity of isorhamnetin on BSA using all the sugars at 14^th and 21^st day of incubation using SDS - PAGE. Our study showed that increase in concentration of glucose, fructose and ribose (0 - 50mM) showed a dose dependent decrease in migration of protein implying increased glycation of BSA. Isorhamnetin (100μM) exhibited antiglycation activity for fructose (30mM) at 14^th day onwards and for glucose (30mM) was at 21^st day onwards. But isorhamnetin did not exert antiglycation activity for ribose (30mM) on both 14^th and 21^st day of incubation. Our study establishes the antiglycation activity of isorhamnetin however further invivo studies are necessary to warrant this activity.